Table 3. Overall and site-specifica standardised incidence ratios and absolute excess risks of second primary neoplasms for bone sarcoma survivors within the British Childhood Cancer Survivor Study (BCCSS).

	All bone sarcoma survivors
	Overall			<25 Years follow-upb			⩾25 Years follow-upb			Osteosarcoma survivors			Ewing sarcoma survivors
SPN	O/E	SIR (95% CI)	AER (95% CI)c	O/E	SIR (95% CI)	AER (95% CI)c	O/E	SIR (95% CI)	AER (95% CI)c	O/E	SIR (95% CI)	AER (95% CI)c	O/E	SIR (95% CI)	AER (95% CI)c	P-valued
Any cancer site	49/11.2	4.4 (3.3, 5.8)	29.3 (18.7, 39.9)	44/5.3	8.4 (6.1, 11.2)	34.7 (23.1, 46.3)	5/5.9	0.8 (0.3, 2.0)	−5.1 (−30.2, 20.0)	23/6.0	3.9 (2.6, 5.8)	26.1 (11.7, 40.5)	19/2.8	6.7 (5.3, 10.6)	35.7 (16.9, 54.6)	0.070
Breast	12/2.6	4.5 (2.6, 8.0)	7.2 (2.0, 12.5)	10/0.9	10.8 (5.2, 19.9)	8.1 (2.6, 13.7)	2/1.7	1.2 (0.1, 4.2)	1.6 (−14.2, 17.5)	6/1.5	4.0 (1.8, 8.8)	6.9 (−0.5, 14.2)	5/0.6	7.8 (3.2, 18.6)	9.6 (−0.1, 19.3)	0.236
Bone	13/0.1	136.3 (79.2, 234.8)	10.0 (4.5, 15.5)	13/0.1	154.3 (82.2, 263.8)	11.6 (5.2, 17.9)	0/−	NP	NP	3/0.05	65.4 (21.1, 202.7)	4.5 (−0.7, 9.7)	8/0.04	223.0 (111.5, 445.9)	17.6 (5.4, 29.8)	0.057

Abbreviations: AER=absolute excess risk; CI=confidence intervals; E=expected number; NA=not applicable; NP=not possible to reliably calculate due to very small expected number; O=observed number; SIR=standardised incidence ratios; SMR=standardised mortality ratios.

^aResults are only reported for site-specific SPNs with at least five observed events overall. Other SPNs were: four genitourinary, four bladder, three digestive, three connective and soft tissue, three malignant neoplasms with unspecified sites, two gliomas, two Hodgkin lymphoma, two NHL, two leukemia, one respiratory, one eye, one thyroid.

^bFrom five-year survival.

^cAER is shown per 10 000 person-years.

^dComparing SIRs for osteosarcoma and Ewing sarcoma survivors.

SIRs and AERs where there are <5 observed events should be interpreted with caution.